Efficacy and Safety of a Novel Gene Therapy (URO-902; PVAX/HSLO) in Female Patients With Overactive Bladder and Urge Urinary Incontinence: Results From a Phase 2A Trial.
Document Type
Conference Proceeding - Restricted Access
Publication Date
5-2022
Publication Title
Journal of Urology
Abstract
Volume
207
Issue
Suppl 5
First Page
e1048
Recommended Citation
Peters K, Enemchukwu E, Kalota S, Robertson K, Greene H, Badger H, et al. Efficacy and safety of a novel gene therapy (URO-902; PVAX/HSLO) in female patients with overactive bladder and urge urinary incontinence: results from a phase 2A trial. J Urol. 2022 May;207(Suppl 5):e1048. doi:10.1097/JU.0000000000002671.03.
DOI
10.1097/JU.0000000000002671.03
COinS
Comments
American Urological Association Annual Meeting, May 13-16, 2022, New Orleans, LA.
International Continence Society Annual Meeting, September 7-10, 2022, Vienna, Austria.
Peters K, Enemchukwu E, Kalota S, Robertson K, Greene H, Badger H, et al. Efficacy and safety of a novel gene therapy (URO-902;PVAX/HSLO) in female patients with overactive bladder and urge urinary incontinence: results from a phase 2A trial. Continence. 2022 Jun;2(Suppl 2):100196. doi:10.1016/j.cont.2022.100196.